Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

69.75USD
2 Dec 2016
Change (% chg)

$1.10 (+1.60%)
Prev Close
$68.65
Open
$68.40
Day's High
$71.55
Day's Low
$67.60
Volume
352,870
Avg. Vol
387,400
52-wk High
$83.93
52-wk Low
$35.37

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics says appointment of James M. Detore as CFO
Monday, 8 Aug 2016 10:54am EDT 

Proteostasis Therapeutics Inc : Says appointment of James M. Detore as Chief Financial Officer .Detore joins company from Bluebird Bio, Inc.  Full Article

Bluebird bio reports qtrly loss per share of $1.59
Wednesday, 3 Aug 2016 04:05pm EDT 

Bluebird Bio Inc : Bluebird bio reports second quarter 2016 financial results and recent operational progress . Qtrly loss per share $1.59 .Q2 earnings per share view $-1.44 -- Thomson Reuters I/B/E/S.  Full Article

Bluebird Bio says co, Lonza Houston enter into manufacturing agreement
Thursday, 9 Jun 2016 08:20am EDT 

Bluebird Bio Inc : Bluebird Bio Inc says Lonza Houston Inc and co have entered into a strategic manufacturing agreement .Says agreement provides for future commercial production of Bluebird Bio's Lenti-D and Lentiglobin drug products..  Full Article

bluebird bio announces transition of chief financial officer
Thursday, 25 Feb 2016 04:05pm EST 

bluebird bio:Says that Jim DeTore, chief financial officer, has decided to leave the company, effective March 18.Bluebird bio is appointing Jeffrey Walsh as chief financial and strategy officer, effective March 1, 2016.  Full Article

bluebird bio and ViroMed Enter into License Agreement for Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
Thursday, 3 Dec 2015 08:00am EST 

bluebird bio, Inc. and ViroMed Co., Ltd:Says they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed's humanized antibody to an undisclosed cancer target for solid tumors.Under the terms of the agreement, ViroMed will provide bluebird bio exclusive rights to its novel humanized antibody to the target, and bluebird bio will leverage its lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.Financial terms of the agreement include a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved.ViroMed is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities.  Full Article

Bluebird Bio, Inc announces proposed public offering of common stock
Tuesday, 23 Jun 2015 04:01pm EDT 

Bluebird Bio, Inc:Says commenced an underwritten public offering of $400 million of its common stock.BofA Merrill Lynch, Morgan Stanley and Cowen and Company are acting as joint book-running managers of the proposed offering.SunTrust Robinson Humphrey, Wedbush PacGrow and Roth Capital Partners are acting as co-managers.  Full Article

Kite Pharma, bluebird to develop therapy to treat HPV-associated cancers
Monday, 22 Jun 2015 08:00am EDT 

Kite Pharma Inc and Bluebird Bio Inc:Says strategic collaboration to advance second generation TCR cell therapy products to treat HPV-associated cancers.Companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 e6 oncoprotein.  Full Article

bluebird bio Inc and Five Prime Therapeutics Inc enter into license agreement
Tuesday, 26 May 2015 04:05pm EDT 

bluebird bio Inc and Five Prime Therapeutics Inc:Says they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Five Prime's human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors.Says under terms of agreement, Five Prime will provide bluebird bio exclusive rights to novel human antibodies to the target, and bluebird bio will leverage lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.Says financial terms of agreement include a $1.5 million upfront payment and subsequent payments to Five Prime, which together could total over $130 million per licensed product if certain development, regulatory, and commercial milestones are achieved.Says Five Prime is also eligible to receive tiered royalties on product sales.  Full Article

bluebird bio receives breakthrough therapy designation to LentiGlobin for treatment of beta-thalassemia major
Monday, 2 Feb 2015 07:00am EST 

bluebird bio Inc:Says the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin((reg))BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major.  Full Article

bluebird bio, Inc announces pricing of public offering of common stock
Monday, 15 Dec 2014 09:14pm EST 

bluebird bio Inc:Announces pricing of an underwritten public offering of 2,650,000 shares of its common stock at a public offering price of $85.00 per share, before underwriting discounts.In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 397,500 shares of common stock.BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers of the proposed offering.SunTrust Robinson Humphrey, Wedbush PacGrow Life Sciences and Roth Capital Partners are acting as co-managers.The offering is expected to close on or about Dec. 19, 2014.  Full Article

Photo

Wall Street little changed as bank rally pauses

U.S. stocks ended little changed on Friday after a payrolls report did little to recast expectations for an interest rate hike from the Federal Reserve this month and bank stocks cooled to round out their fourth straight week of gains. | Video